Editorial
|
|
|
|
|
A prerequisite for establishing trust
|
|
|
|
Marketing Authorisations
|
|
|
|
|
For a minority of patients
|
|
|
|
|
|
|
|
|
|
No better than sevelamer hydrochloride
|
|
|
|
|
|
|
|
|
|
|
|
More rapid castration and nothing more
|
|
|
|
|
|
|
|
|
|
More prudent to continue using exenatide
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Still no convincing results
|
|
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Usually bilateral and reversible
|
|
|
|
|
|
|
|
|
|
Telithromycin effects especially severe
|
|
|
|
|
|
|
|
|
|
To be weighed in the balance
|
|
|
|
|
|
|
|
|
|
|
|
A meta-analysis contradicting previous data
|
|
|
|
|
|
|
|
|
|
Suspended from the French market
|
|
|
|
|
|
|
|
|
|
Consistent and worrying data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adverse effects piling up
|
|
|
|
|
|
|
|
|
|
Withdraw promptly at first signs
|
|
|
|
|
|
Reviews
|
|
|
|
|
Slightly fewer deaths from ventricular fibrillation
|
|
|
|
|
|
|
|
|
|
|
|
Too many uncertainties to recommend routine screening
|
|
|
|
|
|
|
|
|
|
An option for severe malaria
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|